Intercept Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for chronic liver diseases. Its lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) being developed as a second-line treatment for primary biliary cirrhosis (PBC) in patients with inadequate response to or intolerance of ursodiol. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept leverages expertise in bile acid chemistry and owns worldwide rights to OCA outside Japan and China, where it has out-licensed the candidate to Dainippon Sumitomo Pharma. The company is led by president and CEO Mark Pruzanski, MD. It recently completed a $30M Series C financing to build its pipeline. Intercept Pharmaceuticals is a New York-based clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic fibrotic and metabolic diseases. Its most advanced programs center on modified bile acids that are selective for the nuclear receptor FXR and the G protein-coupled receptor TGR5. The company intends to advance these clinical programs and continue building a pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors. Intercept completed a $25M Preferred Series B financing provided by its majority shareholder Genextra S.p.A. Genextra’s backing is expected to enable the company to progress its clinical work while expanding its pipeline. Company leadership includes Dr. Mark Pruzanski (founder, President and CEO) and, in conjunction with the financing, Dr. Lorenzo Tallarigo (CEO of Genextra and Intercept director) is assuming the role of Chairman.

Total raised

$55M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2012